Venrock Healthcare Capital Partners
3 rounds tracked since 15 October 2025.
- Rounds
- 3
- Led
- 2
- Capital in these rounds
- $708M
Sectors
Countries
Rounds
- CellCentricLeadDevelops inobrodib, an oral p300/CBP inhibitor for multiple myeloma $220MSeries D · 6 May
- Angitia BiopharmaceuticalsClinical-stage drugs for musculoskeletal and bone diseases $130MSeries D · 5 Feb
- TubulisLeadDevelops antibody-drug conjugates for cancer $358MSeries C · 15 Oct
No round matches these filters.